Results 191 to 200 of about 2,947,895 (397)

In-hospital predictors of post-stroke depression for targeted initiation of Selective Serotonin Reuptake Inhibitors (SSRIs) [PDF]

, 2022
Julie Yi, Justin Lu, Annie Yang, Elisabeth B. Marsh   +3 more
openalex   +1 more source

New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal

Psychotherapy and Psychosomatics, 2015
G. Chouinard, V. Chouinard
semanticscholar   +1 more source

Brief report: Ketamine‐assisted “bridge therapy” for opioid tapering in complex cases

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25‐year‐old woman with OUD, chronic pain, and major depressive disorder underwent an 8‐week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Results Methadone
Mariana C. de Oliveira, Cláudia C. de Araujo Palmeira, André B. Negrão, Ziyad A. Hadi, Julia R. Arana, Rita de Cássia Ferreira Duarte, Joice L. P. da Silva, Gustavo K. Matsui, João F. D. Rapozero, Douglas H. Crispim, André Malbergier, João M. Castaldelli‐Maia   +11 more
wiley   +1 more source

Dapoxetine, a Selective Serotonin Reuptake Inhibitor, Suppresses Zika Virus Infection In Vitro. [PDF]

Molecules, 2023
Zhang B, Yu J, Zhu G, Huang Y, Zhang K, Xiao X, He W, Yuan J, Gao X.   +8 more
europepmc   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

JAMA psychiatry, 2014
D. Umbricht, D. Alberati, M. Martin-Facklam, E. Borroni, E. Youssef, M. Ostland, T. Wallace, F. Knoflach, E. Dorflinger, J. Wettstein, A. Bausch, G. Garibaldi, L. Santarelli   +12 more
semanticscholar   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning

, 2012
Holden D. Brown, Dionisio A. Amodeo, John A. Sweeney, Michael E. Ragozzino   +3 more
openalex   +2 more sources

Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension [PDF]

, 2013
Ali Sadoughi, Kari E. Roberts, Ioana R. Preston, Ginny P. Lai, Deborah H. McCollister, Harrison W. Farber, Nicholas S. Hill   +6 more
openalex   +1 more source

Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.

JAMA Internal Medicine, 2014
H. Joffe, K. Guthrie, A. LaCroix, S. Reed, K. Ensrud, J. Manson, K. Newton, E. Freeman, G. Anderson, J. Larson, J. Hunt, J. Shifren, K. Rexrode, B. Caan, B. Sternfeld, J. Carpenter, L. Cohen   +16 more
semanticscholar   +1 more source